Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 13/20 | 0.63 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 0.63 |
| ▸ | KDM1A | O60341 | 5/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471052 | 0.91 | CDK5 (0.66) | CDK5CDK5R1KDM1AMAOAMEN1 | |
| SCHEMBL5458326 | 0.86 | CDK5 (0.48) | CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL5460912 | 0.83 | CDK5 (0.63) | CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL6675807 | 0.82 | CDK5 (0.53) | CDK5CDK5R1KDM1AMAOAMEN1 | |
| Bromide SCHEMBL5466706 | 0.82 | CDK5 (0.62) | CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL6675811 | 0.79 | CDK5 (0.53) | CDK5CDK5R1KDM1AMEN1KMT2A | |
| SCHEMBL14582110 | 0.77 | TYR (0.60) | CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL5462206 | 0.77 | CDK5 (1.00) | CDK5CDK5R1KMT2A | |
| SCHEMBL5475254 | 0.76 | CDK5 (0.67) | CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL5469453 | 0.76 | CDK5 (0.61) | CDK5CDK5R1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | CDK5 27/4885CDK5R1 147/4885KDM1A 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.